Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide.
Walenga
J M
JM
Department of Pathology, Loyola University Medical Center, Maywood, Illinois 60153, USA.
Jeske
W P
WP
Bara
L
L
Samama
M M
MM
Fareed
J
J
D000818:Animals; D000925:Anticoagulants / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D000990:Antithrombin III / Q000378:metabolism; D001665:Binding Sites; D001792:Blood Platelets / Q000187:drug effects; D002240:Carbohydrate Sequence; D065427:Factor Xa Inhibitors; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D066298:In Vitro Techniques; D008969:Molecular Sequence Data; D015394:Molecular Structure; D009844:Oligosaccharides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D013927:Thrombosis / Q000517:prevention & control
D000925:Anticoagulants; D065427:Factor Xa Inhibitors; D009844:Oligosaccharides; C049714:IC 831423; D000990:Antithrombin III; D006493:Heparin